Pembrolizumab monotherapy in patients with previously untreated NSCLC with ≥50% PD-L1 expression demonstrated superiority in the median progression-free survival (PFS) and OS over the platinum-based chemotherapy (KEYNOTE-024 trial) [10]. Here, CD274 is linked to non-small cell lung carcinoma.